Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.31 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1832146 | 0.99 | NAMPT (0.35) | NAMPTHTR6TYK2JAK3CASP6 | |
| Succinic Acid SCHEMBL1831567 | 0.94 | NAMPT (0.35) | NAMPTHTR6CASP6KAT5KAT8 | |
| Cadaverine Tartrate SCHEMBL1833475 | 0.92 | NAMPT (0.35) | NAMPTKAT5KAT8 | |
| Cadaverine Tartrate SCHEMBL2194462 | 0.92 | NAMPT (0.35) | NAMPTKAT5KAT8 | |
| SCHEMBL1831300 | 0.91 | NAMPT (0.32) | NAMPTPIP4K2APIP4K2C | |
| SCHEMBL1831984 | 0.91 | NAMPT (0.34) | NAMPTHTR6PIP4K2APIP4K2CKAT5 | |
| Hydrochloric Acid SCHEMBL1834884 | 0.90 | NAMPT (0.34) | NAMPTHTR6KAT5KAT8 | |
| SCHEMBL1580807 | 0.89 | FGFR4 (0.35) | HTR6CHRNB2KAT5KAT8SLC40A1 | |
| SCHEMBL1831993 | 0.89 | MET (0.35) | NAMPTHTR6SLC40A1 | |
| SCHEMBL1580974 | 0.88 | HTR6 (0.42) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318390-A1 | PYRROLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-05-11 | — | — | EP | claimed |
| WO-2010024451-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | claimed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | claimed |
| EP-3329921-B1 | TABLET | TAKEDA PHARMACEUTICALS CO (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-108135915-B | Tablet formulation | 武田药品工业株式会社 | 2021-06-25 | — | — | CN | disclosed |
| US-10835541-B2 | Tablet | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-17 | — | — | US | disclosed |
| US-20180214460-A1 | TABLET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| EP-3329921-A1 | TABLET | Takeda Pharmaceutical Company Limited (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-8993598-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8969387-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140031393-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8592597-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2318390-B1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2318390-A1 | PYRROLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010024451-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056577-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | NAMPT 1814/4885HTR6 233/4885TYK2 1538/4885 |
| US-20140031393-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | NAMPT 1814/4885HTR6 233/4885TYK2 1538/4885 |
| US-20110172275-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | NAMPT 1814/4885HTR6 233/4885TYK2 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.